CanImGuide Therapeutics

CanImGuide Therapeutics is a Swedish biopharmaceutical company developing a novel class of cancer immunotherapies designed to reverse tumor-induced immunosuppression. The company's research is based on the discovery of albumin-derived neo-structures that act as physiological blockers of the LFA-1 receptor, a critical component for immune cell activation and tumor infiltration. Its lead candidate, P28R, is a synthetic peptide that binds to and neutralizes these immunosuppressive neo-structures, thereby restoring the immune system's ability to recognize and destroy cancer cells. CanImGuide has demonstrated significant efficacy in spontaneous canine tumors and has progressed P28R into First-in-Man clinical trials for patients with advanced solid tumors. The company's approach aims to provide a complementary or alternative strategy to existing checkpoint inhibitors, particularly for the large population of patients who do not respond to current therapies.